Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease
2017-000402-38Phase 2Unknown
- Sponsor
- Gilead Sciences
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in inflammatory bowel disease (IBD) and autoimmune colitis comparing Filgotinib with Placebo (2 arms). Primary endpoint: Proportion of subjects with ≥ 50% decrease in sperm concentration at Week 13. Status: unknown.
02
Drugs
filgotinib
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitis
Beyond the preview
Go deeper on 2017-000402-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000402-38.